Shell Asset Management Co. bought a new position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,565 shares of the biotechnology company’s stock, valued at approximately $561,000.
Other institutional investors also recently bought and sold shares of the company. Smith Asset Management Group LP acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $173,000. Victory Capital Management Inc. acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $245,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Enanta Pharmaceuticals during the third quarter worth approximately $311,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Enanta Pharmaceuticals by 22.6% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 3,747 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 690 shares in the last quarter. Finally, Yorktown Management & Research Co Inc purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $602,000. 85.18% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on ENTA. BidaskClub downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. TheStreet downgraded Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, November 26th. Finally, Oppenheimer set a $100.00 price target on Enanta Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, August 14th. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $104.00.
In other news, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $95.32, for a total value of $396,054.60. Following the transaction, the vice president now owns 4,155 shares in the company, valued at $396,054.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tim Ocain sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $83.64, for a total value of $2,091,000.00. The disclosure for this sale can be found here. Corporate insiders own 10.56% of the company’s stock.
Shares of ENTA stock opened at $73.03 on Friday. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 20.99 and a beta of 0.91. Enanta Pharmaceuticals Inc has a 12-month low of $47.49 and a 12-month high of $127.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 26th. The biotechnology company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The company had revenue of $67.20 million for the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. Enanta Pharmaceuticals’s revenue for the quarter was down 11.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.86 earnings per share. As a group, equities analysts forecast that Enanta Pharmaceuticals Inc will post 1.7 EPS for the current fiscal year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Story: Liquidity
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.